A Phase 3 Safety and Efficacy Study of Baloxavir Marboxil in Children Less Than 1 Year Old With Suspected or Confirmed Influenza
Baloxavir was well tolerated in children <1 year of age, with no new safety signals identified. Clinical, virological and safety outcomes were consistent with established profiles in adults, adolescents and children 1-<12 years old.
Authors
- Steffen Wildum (ORCID: https://orcid.org/0000-0001-9779-5740)
- Manisha Kanwar
- Laura Burleigh Macutkiewicz
- Sauli Palmu (ORCID: https://orcid.org/0000-0003-3270-7660)
- Jeffrey P. Baker
- Mercedes Macías Parra
- Larisha Pillay-Ramaya
- Katherine Kocsis
- Eriola Berisha
Institutions
- Roche (Switzerland) (CH)
- Roche (Canada) (CA)
- Roche (United Kingdom) (GB)
- Tampere University Hospital (FI)
- Tampere University (FI)
- Instituto Nacional de Pediatria (MX)
Publication Details
- Journal
- The Pediatric Infectious Disease Journal
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1097/inf.0000000000004826
- Citations
- 8
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 10.83
Funders
- Roche